Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
Get Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharma (NASDAQ: AMLN) reported Q2 loss of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $158.07 million versus the consensus estimate of $157.72 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
- Stride Inc. (LRN) Tops Q3 EPS by 17c, provides guidance
- Chubb Corp. (CB) Tops Q1 EPS by 10c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!